The Innovation Mandate: Strengthening the Biopharma Ecosystem for the Next Generation

The biopharma industry has reached a critical inflection point. While pioneering new scientific frontiers, the industry faces challenges from global budgetary pressures and, in the U.S., structural distortions and renewed attempts to implement domestic price-setting policies that threaten to erode the U.S. competitive advantage. These and other dynamics could radically shift global leadership and patient access. This panel explores our industry's standing in a global economy where surging international competitors are rapidly scaling innovation and attracting capital. It will examine the U.S.’s future-readiness and discuss how to better establish biopharma’s vital role as a strategic national asset—essential for, among other things, medical progress, economic strength, and preparedness. Finally, the group will discuss proactive public policy ideas that can move beyond defensive measures and solidify the U.S. position as a global leader.